AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6320226
Drug: delta 9‐tetrahydrocannabinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delta 9‐tetrahydrocannabinol (THC) 17.5 mg orally
Trial: 6320226
Drug: Nabilone 2
RxNorm normalized name: nabilone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 2 mg orally
Trial: 6320226
Drug: 1-g marihuana
RxNorm normalized name: Mariana Mariana Seed
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g marihuana cigarette containing 1.83% THC, smoked
Trial: 26077620
Drug: Face-to-Face Cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT)
Trial: 31509674
Drug: n-3 group
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 group (fish-oil capsules containing 900 mg of n-3 long-chain polyunsaturated fatty acids)
Trial: 31509674
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vegetable-oil capsules containing trace n-3 long-chain polyunsaturated fatty acids)
Trial: 29038282
Drug: 33% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% daily dosing under directly observed therapy (DOT)
Trial: 29038282
Drug: 67% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67% daily dosing under directly observed therapy (DOT)
Trial: 29038282
Drug: 100% daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% daily dosing under directly observed therapy (DOT)
Trial: 27519769
Drug: Telmisartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20 mg/day) for 12 weeks
Trial: 27519769
Drug: Telmisartan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (30 mg/kg/day, orally) for 7 days
Trial: 23238507
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol infusion 1-3 mg per hour
Trial: 23238507
Drug: Biatrial pacing
RxNorm normalized name: sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biatrial pacing and oral metoprolol (50-150 mg daily for 72 hours)
Trial: 23238507
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol infusion
Trial: 23238507
Drug: Biatrial pacing
RxNorm normalized name: sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biatrial pacing and oral metoprolol
Trial: 15793459
Drug: Glycolic acid
RxNorm normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycolic acid application (initially at home for 2 weeks, followed by higher concentration in-office weekly for six applications)
Trial: 15793459
Drug: Multivitamin product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin product (topical application at home daily for 3 months)
Trial: 15793459
Drug: Cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream base (placebo) for 3 months
Trial: 1781798
Drug: Gallopamil (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (0.02 mg/kg/h followed by 0.03 mg/kg/h after 24 hours)
Trial: 25119953
Drug: Drug Facts
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Facts
Trial: 15329504
Drug: Bepridil alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil alone or in combination with aprindine
Trial: 15329504
Drug: Electrical conversion
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical conversion with conventional antiarrhythmic drugs other than bepridil and aprindine
Trial: 15329504
Drug: Bepridil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil treatment
Trial: 11601567
Drug: AND-HB (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AND-HB (300 mg androstenediol, 480 mg saw palmetto, 450 mg indole-3-carbinol, 300 mg chrysin, 1500 mg gamma-linolenic acid, 1350 mg Tribulus terrestris per day)
Trial: 9685822
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg, twice daily for a week)
Trial: 9685822
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for a week)
Trial: 8027274
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) co-treatment with human menopausal gonadotrophins (HMG) and human chorionic gonadotrophin (HCG)
Trial: 797678
Drug: Prophylactic central
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic central nervous system (CNS) therapy
Trial: 797678
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic CNS therapy (Control)
Trial: 797678
Drug: Prophylactic CNS
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic CNS therapy
Trial: 25940329
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose in water solution (group G5W)
Trial: 19968380
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with more than 9 sessions
Trial: 19968380
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with problem-solving treatment component
Trial: 19968380
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with social skills treatment component
Trial: 15447898
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg folic acid in a tablet
Trial: 11489002
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and gemcitabine (first-line treatment)
Trial: 11489002
Drug: Gemcitabine, paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, paclitaxel, and cisplatin or carboplatin (triplet therapy)
Trial: 11489002
Drug: Gemcitabine, paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, paclitaxel, and carboplatin (combination treatment)
Trial: 3421208
Drug: 5-100 g
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-100 g linseed oil
Trial: 3421208
Drug: linolenic acid
RxNorm normalized name: Linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: linolenic acid absorption
Trial: 27914501
Drug: Intravenous levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levosimendan (0.2 μg kg‐1 min‐1 for the first hour followed by 0.1 μg/kg for 23 hours)
Trial: 22013887
Drug: Dual-wave insulin
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-wave insulin boluses for pizza dinner (45g carbohydrates, 400kcal from fat-protein)
Trial: 22013887
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group using standard insulin dose calculation (n Carbohydrate Units×ICR)
Trial: 20711065
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical and occupational therapy (daily sedative interruption followed by therapy every hospital day)
Trial: 16351775
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate syrup (20 mg elemental Fe twice daily) + single dose of vitamin A (33,000 microg)
Trial: 16351775
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + single dose of vitamin A (33,000 microg)
Trial: 12438295
Drug: no beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no beta-blockers
Trial: 10876850
Drug: Concentrated inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated inactivated tissue-culture tick-borne encephalitis vaccine
Trial: 8607736
Drug: EMG biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG biofeedback treatment (one 45-minute session)
Trial: 8607736
Drug: Additional biofeedback
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional biofeedback treatment sessions (average of 3 sessions)
Trial: 21075062
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP™) - 112mg via Novartis T‐326 Inhaler
Trial: 21075062
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TIS, TOBI®) - 300mg/5mL via PARI LC® PLUS nebulizer
Trial: 21075062
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP™)
Trial: 21075062
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution (TIS, TOBI®)
Trial: 12468450
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (immunosuppressive drug) paired with a distinctively flavored drink (conditioned stimulus)
Trial: 12468450
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules paired with the conditioned stimulus (drink)
Trial: 9475269
Drug: molsidomine retard,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molsidomine retard, 8 mg b.i.d.
Trial: 9475269
Drug: molsidomine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molsidomine, 4 mg t.i.d.
Trial: 2797640
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (3 doses of 1-g intravenous cefazolin before, during, and 6-8 hours after surgery)
Trial: 15379051
Drug: Verorab vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verorab vaccine (3 intramuscular doses at days 0, 7, and 28)
Trial: 15379051
Drug: CRL vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRL vaccine (4 subcutaneous doses at days 0, 3, 7, and 28)
Trial: 9580255
Drug: Interferon-alpha2b, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2b, 5 million units, subcutaneously daily for 16 weeks
Trial: 9580255
Drug: Prednisone for
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks
Trial: 7973768
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and radiation therapy followed by resection
Trial: 3057852
Drug: Disopyramide 150
RxNorm normalized name: disopyramide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 150 mg 4 times a day
Trial: 3057852
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg 4 times a day
Trial: 28428187
Drug: Fixed distribution
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed distribution of a coupon to collect HIVST from a drug store or health post
Trial: 22782539
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose with dabigatran etexilate 150 mg bid (part 1)
Trial: 22782539
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose with dabigatran etexilate 150 mg bid (part 3)
Trial: 22782539
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg qd with dabigatran etexilate 150 mg bid (part 2)
Trial: 18463543
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (surya namaskara, pranayama, avartan dhyan)
Trial: 16129526
Drug: Intranasal proteosome‐adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal proteosome‐adjuvanted vaccine
Trial: 9052356
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline
Trial: 14498756
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 or 20 mg (on-demand, not more than once daily)
Trial: 16394324
Drug: Priming infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming infusion (5 microg/kg/min) for vecuronium (15 microg/kg)
Trial: 16394324
Drug: Higher priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher priming infusion (10 microg/kg/min) for vecuronium (15 microg/kg)
Trial: 16394324
Drug: Priming infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming infusion (10 microg/kg/min) for vecuronium (20 microg/kg)
Trial: 1783914
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg twice daily (n = 815)
Trial: 1783914
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg once daily (n = 806)
Trial: 31409421
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-testing (HIVST) provided for eligible household members who are absent or decline testing.
Trial: 22488613
Drug: Cemented Exeter
RxNorm normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented Exeter implant
Trial: 22488613
Drug: Uncemented Zweymüller
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncemented Zweymüller Alloclassic implant
Trial: 3893208
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine 100 mg
Trial: 9509973
Drug: BUCY (busulfan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUCY (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg)
Trial: 9509973
Drug: BEAC (carmustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEAC (carmustine 300 mg/m2, etoposide 600 mg/m2, cytarabine 600 mg/m2, and cyclophosphamide 140 mg/kg)
Trial: 23639822
Drug: Conventional diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diclofenac injection
Trial: 21974834
Drug: Multi-professional medication
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-professional medication review at baseline and 6 months
Trial: 21974834
Drug: Multi-professional medication
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-professional medication review
Trial: 14531810
Drug: Loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretic (furosemide or torsemide)
Trial: 14531810
Drug: Daily loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily loop diuretic administration
Trial: 22316334
Drug: Fentanyl 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.5 g kg-1
Trial: 22316334
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 g kg-1
Trial: 18254150
Drug: Levonorgestrel tablet
RxNorm normalized name: Levonorgestrel Tablets
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel tablet formulation 1
Trial: 18254150
Drug: Levonorgestrel tablet
RxNorm normalized name: Levonorgestrel Tablets
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel tablet formulation 2
Trial: 15983467
Drug: Intraoperative remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) (large-dose remifentanil)
Trial: 15983467
Drug: Intraoperative remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative remifentanil at 0.05 microg x kg(‐1) x min(‐1) (small-dose remifentanil)
Trial: 15983467
Drug: Intraoperative remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative remifentanil at 0.40 microg x kg(‐1) x min(‐1) and 0.5 mg/kg ketamine just after induction (large-dose remifentanil-ketamine)
Trial: 10624455
Drug: Pamidronate 150
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 150 mg/day
Trial: 7575752
Drug: Indometacin 75
RxNorm normalized name: Indometacin 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin 75 mg bid
Trial: 7575752
Drug: Indometacin 75
RxNorm normalized name: Indometacin 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin 75 mg bid plus roxatidine acetate 75 mg nocte
Trial: 7575752
Drug: Indometacin 75
RxNorm normalized name: Indometacin 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin 75 mg bid plus roxatidine acetate 75 mg bid
Trial: 1782227
Drug: UDCA (13‐15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (13‐15 mg/kg per day)
Trial: 20419154
Drug: Telaprevir (HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (HCV protease inhibitor), specific dosage and duration not mentioned
Trial: 1813715
Drug: Pseudomonas immunoglobulin
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas immunoglobulin (250 mg/kg) administered intravenously on days 3, 5, 7, 10, and 13 after trauma
Trial: 26460306
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive intervention (25 training sessions at home with weekly coaching)
Trial: 25325208
Drug: Moderate-dose non-liberal-interval
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose non-liberal-interval dosage (MDNLD) regimen (12.5 mg/Kg every 12 hours)
Trial: 25325208
Drug: High-dose extended-interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose extended-interval dosage (HDED) regimen (25 mg/Kg every 24 hours)
Trial: 19254942
Drug: AC (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (doxorubicin 40 mg/m2 plus cyclophosphamide 500 mg/m2)
Trial: 19254942
Drug: D (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D (single-agent docetaxel 60 mg/m2)
Trial: 17767753
Drug: Bixa Orellana
RxNorm normalized name: BIXA ORELLANA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bixa Orellana (BO) 250 mg 3 times a day for 12 months
Trial: 3988415
Drug: Potassium +
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium + Magnesium Aspartate (K + Mg Asp)
Trial: 30998237
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (0.67 mg/m2/day)
Trial: 30004039
Drug: Tadalafil 2.5
RxNorm normalized name: tadalafil 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 2.5 mg once daily
Trial: 30004039
Drug: Tadalafil 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5.0 mg once daily
Trial: 22413962
Drug: Dapagliflozin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin + Metformin
Trial: 18338276
Drug: Morphine PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCEA combined with lornoxicam 8 mg iv
Trial: 18338276
Drug: Morphine PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCEA combined with placebo (saline 2 ml iv)
Trial: 14512205
Drug: Mirtazapine 15-45
RxNorm normalized name: mirtazapine 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15-45 mg (n = 124)
Trial: 14512205
Drug: Paroxetine 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-40 mg (n = 122)
Trial: 1627434
Drug: Adjuvant intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) - 600 mg/m2 each of cyclophosphamide and fluorouracil, and 40 mg/m2 of methotrexate, administered IV on day 1, repeated every 3 weeks for a total of 12 treatments.